Inhibition of multidrug resistance by immunisation with synthetic P-glycoprotein-derived peptides

European Journal of Cancer

Volumn 40, Issue 4, 2004, Pages 606-613

  Pawlak Roblin, C ^a   Tosi, P F ^a   Perrin, L ^a   Devy, J ^a   Venteo, L ^a   Albert, P ^a   Nicolau, C ^b   Madoulet, C ^a  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b AC IMMUNE SA   (Switzerland)

Author keywords

Immunisation; Lipopeptides; Liposomes; Multidrug resistance (MDR); P glycoprotein 170Kd (P170)

Indexed keywords

ALUMINUM POTASSIUM SULFATE; DOXORUBICIN; GLYCOPROTEIN P; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; LIPID A; LIPOSOME; PEPTIDE MPP 1; PEPTIDE MPP 2; PEPTIDE MPP 4; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA P 388; MOUSE; MULTIDRUG RESISTANCE; MURINE LEUKEMIA; NONHUMAN; PALMITOYLATION; PRIORITY JOURNAL;

EID: 1242293828     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.11.019     Document Type: Article

References (43)

1. Endicott J.A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58:1989;137-171.
2. Moscow J.A., Cowan K.H. Multidrug resistance. Cancer Chemother. Biol. Resp. Modif. 11:1990;97-114.
3. Chen C., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., Roninson I.B. Internal duplication and homology with bacterial transport proteins in the mdr-1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 47:1986;381-389.
4. Devault A., Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol. Cell. Biol. 10:1990;1652-1663.
5. Hyde S.C., Emsley P., Hartshorn M.J.et al. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature. 346:1990;362-365.
6. Roninson I.B. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem. Pharmacol. 43:1992;95-104.
7. Hegmann E.J., Bauer H.C., Kerbel R.S. Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res. 52:1992;6969-6975.
8. Schinkel A.H., Smit J.J., Van Tellingen O., Beijnen J.H., Wagenaar E., Van Deemter L. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:1994;491-502.
9. Schinkel A.H., Arceci R.J., Smit J.J.et al. Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein. Int. J. Cancer. 30:1993;478-484.
10. Mechetner E.B., Roninson I.B. Efficient inhibition of P-glycoprotein mediated multidrug resistance with a monoclonal antibody. Proc. Natl. Acad. Sci. U.S.A. 89:2002;5224-5228.
11. Gros P.H., Croop J., Housman D. Mammalian drug resistance gene. complete cDNA sequence indicates a strong homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug resistant human cells Cell. 47:1986;371-380.
12. Smit J.J.M., Schinkel A.H., Oude Elferink R.P.J.et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell. 75:1993;451-462.
13. Tosi P.F., Radu D., Nicolau C. Immune response against the murine mdr1 protein induced by vaccination with synthetic lipopeptides in liposomes. Biochem. Biophys. Res. Com. 212:1995;494-500.
14. Nicolau C., Greferath R., Balaban S.T., Lazarte J.E., Hopkins R.J. A liposome-based therapeutic vaccine against β-amyloid plaques on the pancreas of transgenic NORBA mice. Proc. Natl. Acad. Sci. 99:2002;2332-2342.
15. Richards R.L., Hayre M.D., Hockmeyzr W.T., Alving C.R. Liposomes, lipid A and aluminium hydroxide enhance the immune response to a synthetic malaria sporozoite antigen. Infect. Immun. 56:1988;682-686.
16. Gros P., Buschman E. The mouse multidrug resistance gene family. structural and functional analysis Int. Rev. Cyto. 137C:1993;169-197.
17. Merrifield R.B. Solid phase peptide synthesis. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85:1963;2149-2154.
18. Merrifield R.B. Solid phase synthesis. Science. 232:1986;341.
19. Schnölzer M., Alewood P., Jones A., Alewood D., Kent S.B.H. In situ neutralization in Boc-chemistry solid phase peptide synthesis. Int. J. Peptide Protein Res. 40:1992;180-193.
20. Fries L.F., Gordon D.M., Richards R.L.et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. U.S.A. 89:1992;358-362.
21. Jiao H., Shen W., Ohe Y., Miura K., Tamura T. SaijoN. A new 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for testing macrophage cytotoxicity to L1210 and its drug-resistant cell lines in vitro. Cancer Immunol. Immunother. 35:1992;412-416.
22. Grant S., Rausher F., Jakubowski A., Cadman E. Effect of N-(phosphonacetyl)-L-aspartate on S-azacytidine metabolism in P388 and L1210 cells. Cancer Res. 41:1981;410-414.
23. Lum B.L., Gosland M.P., Kaibish S., Sikic B.I. Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy. 13:1993;88-109.
24. Ford J.M., Hait W.N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42:1990;155-199.
25. Figueredo A., Arnold A., Goodyear M.et al. Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. A phase I/II study. Cancer. 65:1990;1895-1902.
26. Solary E., Caillot D., Chauffert B.et al. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. Clin. Oncol. 10:1992;1730-1736.
27. Trump D.L., Smith D.C., Ellis P.G.et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent. phase I trial in combination with vinblastine J. Natl. Cancer Inst. 84:1992;1811-1816.
28. Beck W.T., Danks M.F. Roninson I.B. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. 1991;3-55 Plenum Press, New York.
29. Hebell T., Ahearn J.M., Fearon D.T. Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science. 254:1991;102-105.
30. Swartz G.M. Jr., Gentry M.K., Amende L.M., Blanchette-Mackie E.J., Alving C.R. Antibodies to cholesterol. Proc. Natl. Acad. Sci. U.S.A. 85:1988;1902-1906.
31. Edelman R. Vaccine adjuvants. Rev. Infect. Dis. 2:1980;370-383.
32. Watari E., Dietzschold B., Szokan D., Heber-Katz E. A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2. J. Exp. Med. 165:1987;459-470.
33. Deres K., Schilf H., Wiesmüller K.H., Jung G., Rammensee H.G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 342:1989;561-564.
34. Bourgault I., Chirat F., Tartar A., Levy J.P., Guillet J.G., Venet A. Simian immunodeficiency virus as a model for vaccination against HIV. J. Immunol. 152:1994;2530-2537.
35. Miller T.P., Grogan T.M., Dalton W.S.N., Spier C.M., Scheper R.J., Salmon S.E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol. 9:1991;17-24.
36. Pierré A., Dunn T.A., Kraus-Berthier L.et al. In vitro and in vivo circumvention of multidrug resistance by servier 9788, a novel triazinoaminopiperidine derivative. Invest. New Drug. 10:1992;137-148.
37. Beck W.T. Do anti-P-glycoprotein antibodies have a future in the circumvention of multidrug resistance? J. Natl. Cancer Inst. 83:1991;1364-1366.
38. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:1993;385-427.
39. Broxterman H.J., Kuiper C.M., Schuurhuis G.J., Tsuruo T., Pinedo H.M., Lankelma J. Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein. Biochem. Pharmacol. 37:1988;2389-2393.
40. Chan H.S.L., Grogan T.M., Haddad G., Deboer G., Ling V.P. P-glycoprotein expression. critical determinant in the response to osteosarcoma chemotherapy J. Natl. Cancer Inst. 89:1997;1706-1715.
41. Efferth T., Volm M. Antibody-directed therapy of multidrug-resistant tumor cells. Med. Oncol. Tumor Pharmacother. 9:1992;11-19.
42. Cole S.P.C., Bhardwaj G., Gerlach J.H.et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1992;1650-1654.
43. Baselga J., Tripathy D., Mendelsohn J.et al. Phase II study of weekly intravenous recombinant humanised anti-p185 HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast. J. Clin. Oncol. 14:1996;737-744.